ARCUTIS BIOTHERAPEUTIC

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

17 4 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Chief Financial Officer Transition

10 4 2025 16:30:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 4 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis and Padagis Agree to Stay Patent Lawsuit

02 4 2025 13:16:46 提供 Nasdaq GlobeNewswire

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

27 3 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

07 3 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 3 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

28 2 2025 09:00:00 提供 Nasdaq GlobeNewswire

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis 

26 2 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

25 2 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

24 2 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

18 2 2025 16:35:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 2 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

27 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

12 1 2025 08:30:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 1 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

16 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 12 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Promotions on Executive Management Team

03 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

13 11 2024 08:00:00 提供 Nasdaq GlobeNewswire